This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr. Matthew Engelhard and Anivarya Kumar In this Friday’s PCT Grand Rounds, Matthew Engelhard and Anivarya Kumar of Duke University will present “A Cross-Sectional Study of GPT-4Based Plain Language Translation of Clinical Notes to Improve Patient Comprehension of Disease Course and Management.” The Grand Rounds session will be held on Friday, March 28, 2025, at 1:00 pm eastern.
After a strong showing in 2024, leading packaged foods company BBB Foods saw their stocks rise from $17.50 to over $28 per share, followed by a successful secondary offering this year. Moreover, Guzman y Gomezs, a renowned Australian fast-casual chain known for a fresh, made-to-order Mexican food experience, whose shares surged 37% on debut, now has its very first location in Illinois.
The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Purple Day 2025, celebrated on March 26, has set sail with the theme Power In Purple, honoring the strength and resilience of individuals living with epilepsy. Organized in collaboration between the Epilepsy Foundation and The Anita Kaufmann Foundation, this years Purple Day highlights the importance of solidarity, visibility and education. Epilepsy is characterized by recurrent, unprovoked seizures caused by irregular brain activity.
Purple Day 2025, celebrated on March 26, has set sail with the theme Power In Purple, honoring the strength and resilience of individuals living with epilepsy. Organized in collaboration between the Epilepsy Foundation and The Anita Kaufmann Foundation, this years Purple Day highlights the importance of solidarity, visibility and education. Epilepsy is characterized by recurrent, unprovoked seizures caused by irregular brain activity.
The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.
The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.
Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. From generative AI tools that draft emails to predictive algorithms that segment target audiences, the speed and scale of innovation are staggering. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates of microbial resistance rise.
The Unseen Hurdles of Generic Drug Development: Lessons Learned As the pharmaceutical industry continues to evolve, one thing remains constant: the pursuit of affordable, high-quality medications for patients worldwide. Generic drugs have long been a vital part of this equation, offering a more accessible alternative to brand-name medications. However, the journey to bringing a generic drug to market is often fraught with challenges.
This is the latest episode of the free DDW narrated podcast, titled Innovation enabled by new drug discovery technologies, which covers two articles written for DDW Volume 24 Issue 3, Summer 2023. They are called: CRISPR breakthroughs: New solutions for common diseases and Re-assessing the risks of drug-induced arrhythmias during drug discovery .
In the fast-evolving field of clinical research, thought leaders do more than just keep up; they lead the charge and shape the direction of the industry. True thought leadership is achieved by consistently providing valuable insights, challenging the status quo and offering innovative solutions that address the fields most pressing challenges. Businesses that establish themselves as trusted voices not only gain credibility but also attract key partnerships and position themselves as pioneers.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new monthly safety bulletins aimed at making medical device and medicine safety information clearer and more accessible for healthcare professionals.
Spring has officially arrived in sunny downtown Philadelphiathe proud home base of Drug Channels. As you can see on the right, we celebrated in Miami at the Drug Channels Leadership Forum. The vernal equinox also brought a surprising surge of industry updates and noteworthy news you wont want to miss: Blue Shield of California provides a puzzling update to its PBM unbundling effort The Stelara biosimilar price war begins My reaction to Optum Rxs pharmacy reimbursement announcement A valuable Fol
As the last date ended on March 21 to submit objections and suggestions on the draft notification issued by Union Ayush Ministry to change the qualification requirements for inspectors to inspect Ayush facilities only with Ayurveda graduates, the All India Drug Control Officers Confederation (AIDCOC) has urged the Union Ayush secretary to reconsider its decision […]
Living with multiple sclerosis (MS) can sometimes feel like youre navigating an unpredictable roadone with unexpected twists, turns, and detours. Theres so much information to absorb, decisions to make, and changes to navigate. At times, it might feel isolatingbut heres the truth: You are not alone in this.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Institutional barriers remain a key driver of health inequities based on race, ethnicity, age, and gender, particularly in the United States. The U.S. Food and Drug Administration (FDA) has taken steps to address these disparities in clinical trial study enrollment over the past two decades, including recent draft guidance issued in June 2024, which mandates diversity action plans for all Phase II and III registrational studies.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
157 
Let's personalize your content